Curis’s partner Genentech to initiate Phase II ovarian cancer trial
Genentech is developing GDC-0449 under a collaboration agreement with Curis and will be the sponsor of this study. GDC-0449 will be evaluated in approximately 100 patients with ovarian
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.